223 related articles for article (PubMed ID: 25278711)
1. Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation.
Rao W; Xie M; Yang T; Zhang JJ; Gao W; Deng YL; Zheng H; Pan C; Liu YH; Shen ZY
World J Gastroenterol; 2014 Sep; 20(36):13159-66. PubMed ID: 25278711
[TBL] [Abstract][Full Text] [Related]
2. Risks and treatment strategies for de novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
Dong C; Gao W; Ma N; Sun C; Zheng WP; Wang K; Shen ZY
Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 27933716
[TBL] [Abstract][Full Text] [Related]
3. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China.
Lei M; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG
World J Gastroenterol; 2018 Dec; 24(48):5525-5536. PubMed ID: 30622380
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
[TBL] [Abstract][Full Text] [Related]
5. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Zhu JJ; Wang SY; Qiu DK
J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of de novo hepatitis B virus infection in pediatric hepatitis B core antibody positive liver graft recipients under prophylactic therapy.
Dong C; Song Z; Chen J; Ma N; Meng X; Sun C; Duan K; Bi B; Wang K; Qin H; Han C; Yang Y; Zhang F; Zheng W; Gao W
J Gastroenterol Hepatol; 2020 May; 35(5):827-832. PubMed ID: 31609494
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Strategy Against De Novo Hepatitis B Virus Infection for Pediatric Recipients Who Receive Hepatitis B Core Antibody-Positive Liver Grafts.
Song Z; Dong C; Meng X; Sun C; Wang K; Qin H; Han C; Yang Y; Zhang F; Zheng W; Chen J; Duan K; Bi B; Gao W
Liver Transpl; 2021 Jan; 27(1):96-105. PubMed ID: 32511854
[TBL] [Abstract][Full Text] [Related]
8. [Application of active immunization in the prevention of de novo hepatitis B virus infection after pediatric liver transplantation with HBcAb positive donor liver].
Cui Y; Lu W; Gao W; Dong C; Han C; Liu Y
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Oct; 29(10):926-930. PubMed ID: 29017655
[TBL] [Abstract][Full Text] [Related]
9. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
[TBL] [Abstract][Full Text] [Related]
10. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation.
Lee KW; Lee DS; Lee HH; Kim SJ; Joh JW; Seo JM; Choe YH; Lee SK
Transplant Proc; 2004 Oct; 36(8):2311-2. PubMed ID: 15561233
[TBL] [Abstract][Full Text] [Related]
11. De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers.
Lee S; Kim JM; Choi GS; Park JB; Kwon CH; Choe YH; Joh JW; Lee SK
Liver Transpl; 2016 Feb; 22(2):247-51. PubMed ID: 26600319
[TBL] [Abstract][Full Text] [Related]
12. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation.
Holt D; Thomas R; Van Thiel D; Brems JJ
Arch Surg; 2002 May; 137(5):572-5; discussion 575-6. PubMed ID: 11982471
[TBL] [Abstract][Full Text] [Related]
13. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience.
Bohorquez HE; Cohen AJ; Girgrah N; Bruce DS; Carmody IC; Joshi S; Reichman TW; Therapondos G; Mason AL; Loss GE
Liver Transpl; 2013 Jun; 19(6):611-8. PubMed ID: 23526668
[TBL] [Abstract][Full Text] [Related]
14. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
15. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants.
Uemoto S; Sugiyama K; Marusawa H; Inomata Y; Asonuma K; Egawa H; Kiuchi T; Miyake Y; Tanaka K; Chiba T
Transplantation; 1998 Feb; 65(4):494-9. PubMed ID: 9500622
[TBL] [Abstract][Full Text] [Related]
16. De novo and apparent de novo hepatitis B virus infection after liver transplantation.
Roche B; Samuel D; Gigou M; Feray C; Virot V; Schmets L; David MF; Arulnaden JL; Bismuth A; Reynes M; Bismuth H
J Hepatol; 1997 Mar; 26(3):517-26. PubMed ID: 9075658
[TBL] [Abstract][Full Text] [Related]
17. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome.
Rokuhara A; Tanaka E; Yagi S; Mizokami M; Hashikura Y; Kawasaki S; Kiyosawa K
J Med Virol; 2000 Dec; 62(4):471-8. PubMed ID: 11074476
[TBL] [Abstract][Full Text] [Related]
18. Kidney Transplantation From Hepatitis B Surface Antigen (HBsAg)-Positive Living Donors to HBsAg-Negative Recipients: Clinical Outcomes at a High-Volume Center in China.
Wang XD; Liu JP; Song TR; Huang ZL; Fan Y; Shi YY; Chen LY; Lv YH; Xu ZL; Li XH; Wang L; Lin T
Clin Infect Dis; 2021 Mar; 72(6):1016-1023. PubMed ID: 32100025
[TBL] [Abstract][Full Text] [Related]
19. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis.
Skagen CL; Jou JH; Said A
Clin Transplant; 2011; 25(3):E243-9. PubMed ID: 21323735
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients.
Wang XD; Feng SJ; Liu JP; Song TR; Huang ZL; Fan Y; Shi YY; Chen LY; Lv YH; Xu ZL; Li XH; Wang L; Lin T
BMC Infect Dis; 2021 Jan; 21(1):41. PubMed ID: 33422017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
